-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $22

Benzinga·11/04/2026 14:23:28
Listen to the news
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $25 to $22.